Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine.
about
Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the EndotheliumMetformin and the gastrointestinal tractPersonalized medicine in Type 2 DiabetesEquilibrative nucleoside transporters-A review.The role of variants regulating metformin transport and action in women with polycystic ovary syndrome.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.Pharmacokinetics of metformin during pregnancy.An update on the pharmacogenomics of metformin: progress, problems and potential.Uptake of pramipexole by human organic cation transporters.Adenosine transport by plasma membrane monoamine transporter: reinvestigation and comparison with organic cationsTaste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands.Tyrosine 112 is essential for organic cation transport by the plasma membrane monoamine transporterColorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene.Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity.Effect of gastric bypass surgery on the absorption and bioavailability of metformin.Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCSElectrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.Residue Ile89 in human plasma membrane monoamine transporter influences its organic cation transport activity and sensitivity to inhibition by dilazepPotent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease InhibitorsExpression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier.Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults.The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersMetformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).Metformin pathways: pharmacokinetics and pharmacodynamicsThe effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers.The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.Polymorphism in human organic cation transporters and metformin action.A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate.Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1.Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancyEffect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy.Renoprotective Effects of Metformin are Independent of Organic Cation Transporters 1 &2 and AMP-activated Protein Kinase in the KidneyTrimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.Pharmacogenetics and personalized treatment of type 2 diabetes
P2860
Q26999344-DC319A9A-65DC-4AB2-B25C-5E2EE6C02985Q28079250-36E28523-2313-40A0-AC32-B47ADE5E65C9Q28542708-6E62A7AF-A06F-4EC7-96DB-5B389617D936Q30244329-65DE8794-0115-49ED-861D-6354384FDC6EQ30275579-F2E65F64-AFE7-4B60-B00A-64EEAD8C9D55Q30571118-A7B25F4B-7102-4C99-9216-B780E58C2A10Q33658321-03D46A86-F340-414E-BC7D-FFA09F4FC9E2Q33861891-811983F3-D813-48EB-B40C-8CFD43EA6FC6Q34003050-0F3FAEE7-AAC0-41C3-AF45-6EE355F4957DQ34037009-25FA4D03-06B5-4B65-81A0-A283859F2358Q34211096-AD291310-4368-47E4-BA38-11BD60F235D0Q34245062-03543967-B75E-46F3-93DB-34757A403836Q34367791-75DD91B8-06EF-4D40-8653-B44B017EEEF3Q34438700-C514BB55-F1DE-4EAF-A79E-0DBC24E0ABBFQ34974839-B116072E-7408-42D5-9E02-72DACACAAA91Q35043256-4D35041F-FF02-4D47-BB08-1AE79FB0DF44Q35429797-F6CB45DC-8E67-41B4-BCC9-0243552C0088Q35675566-6E615DEA-D633-4CCE-A282-B6AF83CCF9B4Q35831312-371B7BE1-00EC-4AD3-BAB8-7511BB4D5A6DQ35952140-A70A4FD0-87BA-484D-89AE-44EC6014F140Q35996455-5368D017-B8E3-404E-A333-8A08B152EFDAQ36024314-72907FB5-EE6B-4178-A400-A3D1B7E33D1CQ36186145-DC684A2C-72D3-4748-B561-B60FE5130DA2Q36186589-08367522-A7D6-4A6E-A8B9-44A6FCDF6E9BQ36579750-0872AC1F-8152-433A-B869-D629AAB2423AQ36689589-B27338F8-46D1-482B-9660-C0F5C481EBF9Q36709745-22973F79-6C47-47BA-A211-34B49F4833A0Q36836472-08AC40A3-73AD-47AF-A385-9A697C59A379Q36908331-FB73E70B-7EF1-4968-BDEF-5E8343C67E16Q36924379-76A478B2-4645-4015-9591-4BED5F8A044EQ37126649-F9FE227D-2093-4A99-AA1B-42684CDEDE52Q37170305-199F6E9D-7A28-4F91-89DD-47239B289A19Q37171418-C9C2BFB6-66F0-49CC-BD59-591BB135B973Q37193773-73ACD19D-B861-4B3E-83AF-08DAD64F2164Q37207844-499C5DE0-0BD5-4C38-A3D5-16CED1D1EADDQ37325586-5939D922-9502-46A8-ACC1-D1D8459C3D19Q37366972-6A8FBA2A-70BB-486E-BC2E-94FC7E292106Q37369333-0BAAF877-45E8-4483-A605-DAD0B678971FQ37428521-D4C0EE0C-0DFD-4F4E-BD6E-AA03835F8E46Q37508445-7BDB1152-F261-47B1-A48C-1F90D749D857
P2860
Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metformin transport by a newly ...... expressed in human intestine.
@en
Metformin transport by a newly cloned proton-stimulated organic cation transporter
@nl
type
label
Metformin transport by a newly ...... expressed in human intestine.
@en
Metformin transport by a newly cloned proton-stimulated organic cation transporter
@nl
prefLabel
Metformin transport by a newly ...... expressed in human intestine.
@en
Metformin transport by a newly cloned proton-stimulated organic cation transporter
@nl
P2093
P2860
P356
P1476
Metformin transport by a newly ...... expressed in human intestine.
@en
P2093
P2860
P304
P356
10.1124/DMD.107.015495
P577
2007-06-28T00:00:00Z